We are live on ! Find out more
IOVA icon

Iovance Biotherapeutics
IOVA

Fund managers haven’t disclosed any holdings of IOVA yet.

IOVA Hedge Fund Activity: Q1 2026 in Review

285 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q1 2026, worth a combined $943M — up 32% from $715M a quarter earlier.

Buyers outnumbered sellers: 64 funds opened new IOVA positions and 39 closed out — a net gain of 25 holders — while 121 added to existing stakes and 58 trimmed.

The largest buyer was Two Sigma Investments, adding an estimated $29.7M. The largest seller was Long Focus Capital Management, cutting an estimated $20.8M.

  • 285 institutional investors held Iovance Biotherapeutics (IOVA) as of Q1 2026, up from 264 in Q4 2025.
  • Funds reported $943M of Iovance Biotherapeutics stock for Q1 2026, up 32% quarter-over-quarter.
  • 64 funds opened new Iovance Biotherapeutics positions in Q1 2026 and 39 closed out, a net change of +25 holders.
  • The largest Iovance Biotherapeutics buyer in Q1 2026 was Two Sigma Investments, an estimated $29.7M added.
  • The largest Iovance Biotherapeutics seller in Q1 2026 was Long Focus Capital Management, an estimated $20.8M sold.

Based on aggregated 13F filings for Q1 2026.